1372702-76-5

Upstream product

• 61592-69-6 (E)-3-(3-Bromo-phenyl)-acryloyl chloride 
• 14473-91-7 3-bromocinnamic acid 
• 22248-14-2 6-hydroxy-2,3,4-trimethoxyacetophenone 
• 3132-99-8 m-bromobenzoic aldehyde 
• 1372702-71-0 C₁₈H₁₇BrO₅ 

Downstream Products

• 1372702-78-7 2-(3-bromophenyl)-5,7-dihydroxy-6-methoxy-4H-chromen-4-one 
• 1637568-99-0 2-(3-bromophenyl)-5-hydroxy-6,7-dimethoxy-4H-chromen-4-one 
• 1637569-04-0 2-(3-bromophenyl)-5,6,7-trihydroxy-4H-chromen-4-one 

Relevant academic research and scientific papers

COMPOSITION AND METHOD FOR TREATING OR PREVENTING INFLUENZA VIRUS INFECTION

The present invention provides a pharmaceutical composition and method for treating or preventing influenza virus infection in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of compounds provided in this invention. In addition, the prevent invention provides new compounds for treating or preventing influenza virus infection.

Synthesis and anti-influenza activities of novel baicalein analogs

A series of novel flavones derivatives were synthesized based on modification of the active ingredients of a traditional Chinese medicine Scutellaria baicalensis GEORGI and screened for anti-influenza activity. The synthetic baicalein (flavone) analogs, especially with the B-rings substituted with bromine atoms, were much more potent than oseltamivir or ribavirin against H1N1 Tamiflu-resistant (H1N1 TR) virus and usually with more favorable selectivity. The most promising were 5b, 5c, 6b and 6c, all displaying an 50% effective concentration (EC50) at around 4.0-4.5 μM, and a selective index (SI=50% cytotoxic concentration (CC50)/EC 50)>70. For seasonal H3N2-infected influenza virus, both 5a and 5b with SI >17.3 indicated superior to ribavirin. The flavonoids having both not-naturally-occurring bromo-substituted B-rings and appropriate hydroxyls positioning on the A-rings might be critical in determining the activity and selectivity against H1N1-Tamiflu-resistant infected influenza viruses.

Oroxylin A analogs exhibited strong inhibitory activities against iNOS-mediated nitric oxide (NO) production

A number of oroxylin A analogs were prepared and evaluated for their inhibitory activities against iNOS-mediated nitric oxide (NO) production from LPS-stimulated BV2 cells. The analogs were synthesized from purchased 2′-hydroxy-4,5,6-trimethoxyacetophenone and aldehydes in 3 steps. Among the tested compounds, several analogs (3b, 3c, 3d, 3f) exhibited strong inhibitory activities. Especially, the analog with 4-nitrophenyl group (3b) showed stronger inhibitory activity (IC50 = 4.73 μM) than that of wogonin (IC50 = 7.80 μM).